Neurogenic diarrhoea after superior mesenteric artery divestment or resection for pancreatic adenocarcinoma following preoperative chemotherapy: international multicentre retrospective study.
Thomas F Stoop, Chiara Croce, Hiroyuki Ishida, Mahsoem Ali, Ammar A Javed, Asif Halimi, Atsushi Oba, Bas Groot Koerkamp, Carl-Stephan Leonhardt, Cornelius A Thiels, Elena Rangelova, Ernesto Sparrelid, Ira Sotirova, Jennifer L Leiting, Jun Tauchi, Kosuke Kobayashi, Marit Klos, Lysanne P M Beuk, Luana Genova, Manuela Mastronardi, Michael L Kendrick, Nabiha A Mughal, Olivier R Busch, Oskar Franklin, Patrik Larsson, Ulla Klaiber, Richard D Schulick, Rutger T Theijse, Oliver Strobel, Poya Ghorbani, Roeland F de Wilde, Salvador Rodriguez Franco, Toshitaka Sugawara, Johanna W Wilmink, Wells Messersmith, Marc G Besselink, Christopher L Wolfgang, Yosuke Inoue, Mark J Truty, Marco Del Chiaro
{"title":"Neurogenic diarrhoea after superior mesenteric artery divestment or resection for pancreatic adenocarcinoma following preoperative chemotherapy: international multicentre retrospective study.","authors":"Thomas F Stoop, Chiara Croce, Hiroyuki Ishida, Mahsoem Ali, Ammar A Javed, Asif Halimi, Atsushi Oba, Bas Groot Koerkamp, Carl-Stephan Leonhardt, Cornelius A Thiels, Elena Rangelova, Ernesto Sparrelid, Ira Sotirova, Jennifer L Leiting, Jun Tauchi, Kosuke Kobayashi, Marit Klos, Lysanne P M Beuk, Luana Genova, Manuela Mastronardi, Michael L Kendrick, Nabiha A Mughal, Olivier R Busch, Oskar Franklin, Patrik Larsson, Ulla Klaiber, Richard D Schulick, Rutger T Theijse, Oliver Strobel, Poya Ghorbani, Roeland F de Wilde, Salvador Rodriguez Franco, Toshitaka Sugawara, Johanna W Wilmink, Wells Messersmith, Marc G Besselink, Christopher L Wolfgang, Yosuke Inoue, Mark J Truty, Marco Del Chiaro","doi":"10.1093/bjsopen/zrag057","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The increased use of superior mesenteric artery (SMA) divestment has been a driver behind the increased resection rate for locally advanced pancreatic cancer following preoperative therapy. This has also resulted in an increase in the rate of postoperative neurogenic diarrhoea, but knowledge about postoperative neurogenic diarrhoea is lacking. The aims of this study were to determine the incidence, risk factors, management, and outcomes of neurogenic diarrhoea after SMA divestment/resection for pancreatic adenocarcinoma.</p><p><strong>Methods: </strong>This multicentre retrospective study included consecutive patients undergoing pancreatic adenocarcinoma resection, including SMA divestment/resection, after preoperative chemotherapy with or without radiotherapy between 2016 and 2022. Primary endpoints were the incidence of postoperative neurogenic diarrhoea, associated factors, treatment strategies, and outcomes. Secondary endpoints were the rate of adjuvant chemotherapy and the impact of neurogenic diarrhoea on overall survival (OS).</p><p><strong>Results: </strong>Overall, 291 patients who underwent pancreatic resection with concomitant SMA divestment (240, 82%) or resection (51, 18%) were included in the study. Postoperative neurogenic diarrhoea was diagnosed in 193 patients. The adjusted risk of developing neurogenic diarrhoea was 59% (95% confidence interval (c.i.) 46 to 73) after ≤ 180° SMA divestment, 80% (95% c.i. 67 to 93) after > 180° SMA divestment, and 77% (95% c.i. 66 to 88) after SMA resection. Postoperative neurogenic diarrhoea was treated with non-opioid drugs (29, 15%), non-opium opioids (140, 73%), opium tincture (69, 36%), and/or octreotide (49, 25%), and normalized in 51% of patients. After adjusting for confounders, neurogenic diarrhoea was not significantly associated with OS (hazard ratio 0.83; 95% c.i. 0.55 to 1.25).</p><p><strong>Conclusion: </strong>Neurogenic diarrhoea occurred in two-thirds of patients following resection of pancreatic adenocarcinoma with concomitant SMA divestment/resection, particularly after > 180° SMA divestment or SMA resection. Although challenging to manage, neurogenic diarrhoea is not associated with impaired OS. Evidence-based treatment strategies are needed for adequate management.</p>","PeriodicalId":9028,"journal":{"name":"BJS Open","volume":"10 3","pages":""},"PeriodicalIF":4.9000,"publicationDate":"2026-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13247994/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BJS Open","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/bjsopen/zrag057","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"SURGERY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: The increased use of superior mesenteric artery (SMA) divestment has been a driver behind the increased resection rate for locally advanced pancreatic cancer following preoperative therapy. This has also resulted in an increase in the rate of postoperative neurogenic diarrhoea, but knowledge about postoperative neurogenic diarrhoea is lacking. The aims of this study were to determine the incidence, risk factors, management, and outcomes of neurogenic diarrhoea after SMA divestment/resection for pancreatic adenocarcinoma.
Methods: This multicentre retrospective study included consecutive patients undergoing pancreatic adenocarcinoma resection, including SMA divestment/resection, after preoperative chemotherapy with or without radiotherapy between 2016 and 2022. Primary endpoints were the incidence of postoperative neurogenic diarrhoea, associated factors, treatment strategies, and outcomes. Secondary endpoints were the rate of adjuvant chemotherapy and the impact of neurogenic diarrhoea on overall survival (OS).
Results: Overall, 291 patients who underwent pancreatic resection with concomitant SMA divestment (240, 82%) or resection (51, 18%) were included in the study. Postoperative neurogenic diarrhoea was diagnosed in 193 patients. The adjusted risk of developing neurogenic diarrhoea was 59% (95% confidence interval (c.i.) 46 to 73) after ≤ 180° SMA divestment, 80% (95% c.i. 67 to 93) after > 180° SMA divestment, and 77% (95% c.i. 66 to 88) after SMA resection. Postoperative neurogenic diarrhoea was treated with non-opioid drugs (29, 15%), non-opium opioids (140, 73%), opium tincture (69, 36%), and/or octreotide (49, 25%), and normalized in 51% of patients. After adjusting for confounders, neurogenic diarrhoea was not significantly associated with OS (hazard ratio 0.83; 95% c.i. 0.55 to 1.25).
Conclusion: Neurogenic diarrhoea occurred in two-thirds of patients following resection of pancreatic adenocarcinoma with concomitant SMA divestment/resection, particularly after > 180° SMA divestment or SMA resection. Although challenging to manage, neurogenic diarrhoea is not associated with impaired OS. Evidence-based treatment strategies are needed for adequate management.